LP
RXRX icon

LMR Partners’s Recursion Pharmaceuticals RXRX Stock Holding History

LMR Partners’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-400,000
Closed -$2.02M – 1624
2025
Q2 		$2.02M Buy
+400,000
New +$1.97M 0.01% 635

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's RXRX Position: Q3 2024 in Review

LMR Partners sold out of Recursion Pharmaceuticals (RXRX) in Q3 2024, closing a stake of 483,595 shares — an estimated $3.63M sold.

LMR Partners first reported a position in RXRX in Q2 2024 and held it in 1 quarter. The position peaked at $3.63M in Q2 2024. 267 funds tracked by Wall St. Rank hold RXRX as of Q3 2024.

  • LMR Partners reported no remaining Recursion Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • LMR Partners sold 483,595 Recursion Pharmaceuticals shares in Q3 2024, an estimated $3.63M.
  • LMR Partners first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • LMR Partners's Recursion Pharmaceuticals position peaked at $3.63M in Q2 2024.
  • 267 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.